1. In this Canadian, randomized controlled trial, the use of primary HPV testing compared with cytology resulted in a significantly lower likelihood of CIN3+ at 48 months. 2. There was also significantly fewer CIN2+ cases in women screened with HPV testing compared with women who were screened with cytology alone at baseline. Evidence Rating: 1 
A retrospective study demonstrates an increase in HPV16-positive status among patients with OPSCC and a corresponding increase in age at diagnosis.
Using a data sample from the CDC National Program for Cancer Registries, investigators determined how demographic factors — age, race, and sex — impact 5-year survival rates for HPV-associated cancers from initial diagnosis until death.
This fact sheet examines possible links between human papillomaviruses (HPVs) and cancer.
Small study also showed that pembrolizumab does not significant impair radiation or chemotherapy dosing.
Protein produced by chronically infected cells in persons with HPV16 infection serves as a biomarker for risk of cancer of the oropharynx.
Self-persuasion is more effective than external persuasion for motivating low-income parents to vaccinate their children against HPV.
The top reasons for not initiating HPV vaccination are necessity, safety, and knowledge, rather than a lack of discussions on sexuality.
Human papillomavirus (HPV)-negative women have low long-term incidence of cervical cancer and CIN3+, which supports an extension of the cervical screening interval beyond five years for some, according to a study.
Patients with oropharyngeal tumors that harbor HPV16 have higher 5-year survival and lower recurrence rates than patients with tumors that harbor other HPV strains or are HPV-negative.
Despite a higher risk for HPV-negative orophayngeal squamous cell carcinoma (OPSCC), poor oral health appears to be associated with OPSCC regardless of HPV status.
Fewer cervical cell anomalies were present on cervical cancer screens of young women in Canada who received the HPV vaccine through a school-based program.
Cervical cancer, and oropharyngeal cancers in men, account for most HPV-associated cancers.
Oncologists should raise awareness of HPV-related cancers and role of vaccinations
Anal cancer is associated with human papillomavirus (HPV) infection, and some women are at increased likelihood of have both diseases.
Posttreatment imaging at 3 months and physical examinations during the 6 months following treatment can detect most recurrences in patients treated with definitive radiation therapy for HPV-associated oropharyngeal cancer.
Among patients treated for oropharyngeal cancers linked to human papillomavirus (HPV) infection, at least 1 HPV-infection antibody could help identify those patients at risk for a recurrence of the cancer.
HPV subtypes 5, 8, 17, 20, and 38 have been associated with a significant increased cancer risk.
Patients with oropharyngeal cancer who were found to have detectable traces of human papillomavirus type 16 (HPV16) in their saliva.
The presence of certain human papillomavirus (HPV)-16 antibodies in the blood is associated with improved survival rates for patients with HPV-related oropharyngeal carcinoma.
One dose of the HPV vaccine may be sufficient to protect girls from cervical cancer rather than the currently recommended three doses.
Detection of human papillomavirus (HPV)16 DNA in oral rinses following treatment for HPV-positive oropharyngeal carcinoma could be a potential tool for long-term tumor surveillance, a study concluded at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Men benefit indirectly but not from cancer risk associated with the virus.
Human papillomavirus (HPV) vaccine may be a cost-effective approach for preventing squamous cell oropharyngeal cancer.
Improved survival and treatment response was seen in HPV-16 positive patients.
A prospective study found that patients with human papillomavirus-related disease had better treatment response than HPV-negative patients.
Investigators have uncovered genomic differences, with potentially important clinical implications, in head and neck cancers caused by infection with the human papillomavirus.
Researchers note that CDC recommends vaccination at age 11 or 12, but only half of girls receiving the vaccination get it at the proper age.
ACOG still recommending women aged 30 to 65 be screened with Pap or HPV/Pap combination, however.
The FDA has approved Gardasil 9 for the prevention of anal, cervical, vaginal, and vulvar cancers.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|